Drug Trial Radar · NCT06516965
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
346
Actual
Start
Oct 10, 2024
Primary completion
Sep 28, 2026
Study completion May 3, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Conditions
- Prurigo Nodularis
Interventions
PovorcitinibDrug
Oral Tablet
PlaceboDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants achieving Itch NRS4 and IGA-CPG-S-TS at Week 24Time frame: Week 24
Locations
119 sites in 11 countries. Site status is shown where the registry gives one.
Medical Dermatology Specialists Phoenix
Phoenix, Arizona
Investigate Md
Scottsdale, Arizona
First Oc Dermatology Research Inc
Fountain Valley, California
Clinical Science Institute Clinical Research Specialists Inc
Santa Monica, California
Center For Clinical and Cosmetic Research
Aventura, Florida
Schweiger Dermatology
Boca Raton, Florida
Direct Helpers Research Center
Hialeah, Florida
Skin Care Research, Llc
Hollywood, Florida
Ziaderm Research, Llc
Miami, Florida
Nodal Medical Center, Llc
Tampa, Florida
Trueblue Clinical Research Moore Clinical Research, Inc McR Tampa Clinic Location
Tampa, Florida
Dermatology Specialists Research
Louisville, Kentucky
University of Maryland School of Medicine
Baltimore, Maryland
Dermatology Associates Pc
Rockville, Maryland
Metro Boston Clinical Partners
Brighton, Massachusetts
Fivenson Dermatology
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Michigan Dermatology Institute
Waterford, Michigan
Allcutis Research, Llc
Portsmouth, New Hampshire
Schweiger Dermatology
Hackensack, New Jersey
OPTISKIN
New York, New York
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Central Sooner Research
Oklahoma City, Oklahoma
Paddington Testing Co Inc
Philadelphia, Pennsylvania
Yardley Dermatology Associates
Yardley, Pennsylvania
Modern Research Associates Pllc
Dallas, Texas
University of Utah Midvalley Dermatology
Murray, Utah
Aesthetic General Dermatology of Seattle
Burien, Washington
Fremantle Dermatology
Fremantle, Australia
Novatrials
Charlestown, New South Wales, Australia
Premier Specialists Pty Ltd
Kogarah, New South Wales, Australia
Skin & Cancer Foundation Australia
Sydney, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Veracity Clinical Research Pty Ltd
Woolloongabba, Queensland, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Az Sint-Jan Brugge Av
Bruges, Belgium
Universitair Ziekenhuis Gent (Uz Gent)
Ghent, Belgium
Grand Hopital de Charleroi - Site Imtr
Gilly, Belgium
Centre Hospitalier Universitaire (Chu) de Liege - Domaine Universitaire Du Sart Tilman
Liège, Belgium
Universite Catholique de Louvain (Ucl) - Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium
Showing 40 of 119 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.